FDA Approves HERNEXEOS — Boehringer Ingelheim Pharmaceuticals, Inc.

# FDA Approves Boehringer Ingelheim's HERNEXEOS (Zongertinib) for Oral Administration Boehringer Ingelheim Pharmaceuticals has received FDA approval for HERNEXEOS (zongertinib), an oral therapeutic agent that expands the company's portfolio in precision medicine and positions it to capture market share in its indication segment. The approval of this new molecular entity could strengthen Boehringer Ingelheim's competitive standing in oncology or targeted therapy markets, pending commercial execution and adoption rates among healthcare providers.